Publications

Detailed Information

Wild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer model

DC Field Value Language
dc.contributor.authorLee, Yong Jin-
dc.contributor.authorChung, June-Key-
dc.contributor.authorKang, Joo Hyun-
dc.contributor.authorJeong, Jae Min-
dc.contributor.authorLee, Myung Chul-
dc.contributor.authorLee, Dong Soo-
dc.date.accessioned2012-07-03T07:57:12Z-
dc.date.available2012-07-03T07:57:12Z-
dc.date.issued2010-02-
dc.identifier.citationEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING; Vol.37 2; 235-241ko_KR
dc.identifier.issn1619-7070-
dc.identifier.urihttps://hdl.handle.net/10371/78298-
dc.description.abstractTo evaluate the role of p53 in radionuclide gene therapy, we investigated the cytotoxic effect of (131)I and (188)Re following cotransfection of the sodium iodide symporter (NIS) and wild-type p53 (wt-p53) genes into cancer cells. The NIS gene was transfected to human anaplastic thyroid carcinoma cells (ARO) expressing mutant p53 (mt-p53) using liposomes. The uptakes of (125)I and (188)Re were measured in the transfected (ARO-N) and wild-type cell lines (ARO). A recombinant adenovirus-5 vector containing a CMV promoter and wt-p53 cDNA, called Ad-p53, was established and transduced to ARO and ARO-N cells. After incubating cells with (131)I and (188)Re, the survival rate of each cell line was measured using a clonogenic assay. For radionuclide gene therapy in an animal model, Ad-p53 was injected directly into ARO and ARO-N tumours which were transplanted to nude mice. Two days later, (188)Re or saline was injected intraperitoneally into the mice, and the tumours were measured using a calliper for 4 weeks. In ARO-N cells, the uptakes of (125)I and (188)Re were 505.16 +/- 21.30 pmol/10(6) cells and 13,875.20 +/- 504.85 cpm/10(6) cells at 30 min, respectively. There was no difference between the survival rates of ARO cells and ARO-N cells after incubation with (131)I or (188)Re. When Ad-p53 was transduced to ARO-N cells, the survival rate of wt-p53-expressing ARO-N cells incubated with (131)I (18.5 MBq/5 ml) and (188)Re (18.5 MBq/5 ml) decreased to 48.8 +/- 18.4% and 32.6 +/- 23.5%, respectively. In the nude mice experiment, ARO and ARO-N tumours gradually grew up to six to eight times larger than the initial volume. ARO and ARO-N tumours transduced with Ad-p53 continued to grow. However, the ARO-N tumours treated with Ad-p53 and 185 MBq of (188)Re regressed to 20% of the initial volume. Growth of ARO-N tumour treated with (131)I or (188)Re was significantly inhibited by Ad-p53 transduction in vivo as well as in vitro. Transfection of the NIS gene into human anaplastic thyroid cancer induced the accumulation of beta-emitter radionuclides, and cotransfection with a wt-p53 gene enhanced the cytotoxic effect.ko_KR
dc.description.sponsorshipThis work was supported by a Korea Research
Foundation Grant funded by the Korean Government (MOEHRD)
(KRF-2003-E-00168)
ko_KR
dc.language.isoenko_KR
dc.publisherSPRINGERko_KR
dc.subjectNISko_KR
dc.subjectRadionuclide gene therapyko_KR
dc.subjectAnaplastic thyroid cancerko_KR
dc.subject(188)Reko_KR
dc.subjectwt-p53ko_KR
dc.subject(131)Iko_KR
dc.titleWild-type p53 enhances the cytotoxic effect of radionuclide gene therapy using sodium iodide symporter in a murine anaplastic thyroid cancer modelko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이용진-
dc.contributor.AlternativeAuthor정준기-
dc.contributor.AlternativeAuthor강주현-
dc.contributor.AlternativeAuthor정재민-
dc.contributor.AlternativeAuthor이동수-
dc.contributor.AlternativeAuthor이명철-
dc.identifier.doi10.1007/s00259-009-1251-5-
dc.citation.journaltitleEUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING-
dc.description.citedreferenceHsieh YJ, 2007, ANTICANCER RES, V27, P2515-
dc.description.citedreferenceD`Avenia P, 2006, CANCER LETT, V231, P102, DOI 10.1016/j.canlet.2005.01.033-
dc.description.citedreferenceLopez-Crapez E, 2005, BRIT J CANCER, V92, P2114, DOI 10.1038/sj.bjc.6602622-
dc.description.citedreferenceLee YJ, 2004, THYROID, V14, P889-
dc.description.citedreferenceFreytag SO, 2004, EXPERT OPIN BIOL TH, V4, P1757, DOI 10.1015/14712598.4.11.1757-
dc.description.citedreferenceLee WW, 2003, ONCOL REP, V10, P845-
dc.description.citedreferenceDohan O, 2003, ENDOCR REV, V24, P48, DOI 10.1210/er.2001-0029-
dc.description.citedreferenceHeltemes LM, 2003, CANCER GENE THER, V10, P14-
dc.description.citedreferenceCarlin S, 2002, NUCL MED BIOL, V29, P729-
dc.description.citedreferenceChung JK, 2002, J NUCL MED, V43, P1188-
dc.description.citedreferenceDadachova E, 2002, NUCL MED BIOL, V29, P13-
dc.description.citedreferenceSasaki R, 2001, INT J RADIAT ONCOL, V51, P1336-
dc.description.citedreferenceHuang M, 2001, CANCER GENE THER, V8, P612-
dc.description.citedreferenceHaberkorn U, 2001, J NUCL MED, V42, P317-
dc.description.citedreferenceKawabe S, 2001, INT J RADIAT BIOL, V77, P185-
dc.description.citedreferenceColletier PJ, 2000, INT J RADIAT ONCOL, V48, P1507-
dc.description.citedreferenceNakamoto Y, 2000, J NUCL MED, V41, P1898-
dc.description.citedreferenceArturi F, 2000, EUR J ENDOCRINOL, V143, P623-
dc.description.citedreferenceSmit JWA, 2000, THYROID, V10, P939-
dc.description.citedreferenceNagayama Y, 2000, J CLIN ENDOCR METAB, V85, P4081-
dc.description.citedreferenceBoland A, 2000, CANCER RES, V60, P3484-
dc.description.citedreferenceHorowitz J, 1999, CURR OPIN MOL THER, V1, P500-
dc.description.citedreferenceMandell RB, 1999, CANCER RES, V59, P661-
dc.description.citedreferenceShimura H, 1997, ENDOCRINOLOGY, V138, P4493-
dc.description.citedreferenceSiles E, 1996, BRIT J CANCER, V73, P581-
dc.description.citedreferenceLAMIOKI H, 1994, RADIOCHIM ACTA, V65, P39-
dc.description.citedreferenceMAHESHWARI YK, 1981, CANCER, V47, P664-
dc.description.tc1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share